Key Segmentation:
By Drug Type
-
Monoclonal Antibodies
-
Vaccines
-
Cell Therapies
-
Interferons and Interleukins
-
Others
By Therapy Area
-
Cancer
-
Autoimmune and Inflammatory Diseases
-
Infectious Diseases
-
Others
By Route of Administration
-
Intravenous
-
Subcutaneous
-
Others
By End User
-
Hospitals and Clinics
-
Research Laboratories
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Merck, Bristol Myers Squibb, Roche, AstraZeneca, Regeneron, GSK, Amgen, Johnson & Johnson, Gilead Sciences, Legend Biotech, BeOne Medicines, Immunocore, Iovance Biotherapeutics, Akeso, Genmab, ImmunityBio, Coherus Oncology and Replimune.
Key opportunities include in vivo and off-the-shelf cell therapies, expansion into autoimmune disease, subcutaneous reformulation of leading antibodies and growth in emerging markets.
Rising cancer incidence, together with expanding approvals of checkpoint inhibitors, bispecific antibodies and cell therapies, is the main growth factor.
By Drug Type, the Monoclonal Antibodies segment dominated the market in 2025 with an estimated 71.42% share, supported by wide use of checkpoint inhibitors across tumor types.
North America dominated the market with a share of 46.09% in 2025, driven by high cancer incidence, early access to new drugs and strong insurance coverage.
